1887
Skip to content
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 39, 01/Oct/2026
  4. Article
Research Open Access
Like 0
Download

Abstract

BACKGROUND

As hepatitis A (HA) incidence declines in Europe and HA virus infections occur later in life, severe disease frequency may increase.

AIM

Among patients hospitalised for HA in France during 2013−2024, we investigated disease severity and mortality associated-risk factors and temporal trends.

METHODS

International Classification of Diseases, 10th Revision codes B150 or B159 as primary discharge diagnosis enabled identifying HA cases from the National Discharge Data Set. Risk factors for severity (hepatic and/or extrahepatic organ failure within 12 weeks post-admission) and mortality were assessed using adjusted odds ratios in original and propensity-matched samples. Trends were determined across five periods covering an HA epidemic in 2017 and the COVID-19 pandemic, with 2013–2016 as reference.

RESULTS

Among 7,923 cases (60.6% male, 39.4% female; median age: 30 years), 28.7% (n = 2,277) developed severe HA, and 1.30% (n = 103) died. Severe HA was associated with older age (+ 15% per decade over 30 years, p < 0.001), male sex (+ 38%, p < 0.001), smoking (+ 23%, p = 0.031), risk factors for chronic liver disease (+ 29%, p = 0.041), and cirrhosis (+ 40%, p = 0.054). Mortality was associated with cirrhosis (2.90-fold increase, p = 0.004), Charlson Comorbidity Index (CCI) ≥ 3 (12.3-fold increase, p < 0.001), and modestly with age (+ 24%, p = 0.005), reaching + 90% (p < 0.001) in models without CCI, indicating a considerable comorbidity effect. From 2013–2016, severe HA and HA-related death risks respectively increased 57% (p < 0.001) and 1.96-fold (p = 0.016) in 2021–2024.

CONCLUSIONS

Severe HA frequency and mortality increased in French hospitals since 2013. Age and male sex were associated with severe disease, and high CCI with mortality. A more extensive, or even universal, vaccination policy could be considered.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.39.2500858
2026-10-01
2026-10-14
/content/10.2807/1560-7917.ES.2026.31.39.2500858
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/39/eurosurv-31-39-2.html?itemId=/content/10.2807/1560-7917.ES.2026.31.39.2500858&mimeType=html&fmt=ahah

References

  1. Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol. 2017;S0168-8278(17)32278-X. PMID: 28887164 
  2. Zeng DY, Li JM, Lin S, Dong X, You J, Xing QQ, et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. J Hepatol. 2021;75(3):547-56.  https://doi.org/10.1016/j.jhep.2021.04.035  PMID: 33961940 
  3. Zhang L, Wang T, Zhou S, Li S, Mo T, Wu S. Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities. Front Public Health. 2025;13:1580863.  https://doi.org/10.3389/fpubh.2025.1580863  PMID: 40487522 
  4. Cao G, Jing W, Liu J, Liu M. The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention. Hepatol Int. 2021;15(5):1068-82.  https://doi.org/10.1007/s12072-021-10232-4  PMID: 34345993 
  5. Andani A, Bunge E, Kassianos G, Eeuwijk J, Mellou K, Van Damme P, et al. Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review. J Viral Hepat. 2023;30(6):497-511.  https://doi.org/10.1111/jvh.13821  PMID: 36825922 
  6. Severi E, Tavoschi L, Carrillo-Santisteve P, Westrell T, Marrone G, Giesecke J, et al. Hepatitis A notifications in the EU/EEA, 2010-2019: what can we learn from case reporting to the European Surveillance System? Euro Surveill. 2023;28(19):2200575.  https://doi.org/10.2807/1560-7917.ES.2023.28.19.2200575  PMID: 37166764 
  7. Andani A, Mellou K, Dewda P, Eeuwijk J, Kassianos G, Van Damme P, et al. Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years. J Viral Hepat. 2025;32(1):e14030.  https://doi.org/10.1111/jvh.14030  PMID: 39526433 
  8. Ndumbi P, Freidl GS, Williams CJ, Mårdh O, Varela C, Avellón A, et al. , Members of the European Hepatitis A Outbreak Investigation Team. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017. Euro Surveill. 2018;23(33):1700641.  https://doi.org/10.2807/1560-7917.ES.2018.23.33.1700641  PMID: 30131095 
  9. Hépatite A en France. Données épidémiologiques 2022-2024. [Hepatitis A in France. Epidemiologic data 2022-2024]. Saint-Maurice: Santé publique France. [Accessed 20 July 2026]. Available from: https://www.santepubliquefrance.fr/index.php/hepatites-virales/hepatite-a/hepatite-a-en-france-donnees-epidemiologiques-2022-2024
  10. Gallian P, Barlet V, Mouna L, Gross S, Morel P, Le Cam S, et al. Persisting higher prevalence of hepatitis A virus RNA in blood donors, France, 2018. Euro Surveill. 2019;24(47):1900695.  https://doi.org/10.2807/1560-7917.ES.2019.24.47.1900695  PMID: 31771700 
  11. World Health Organization (WHO). Immunological basis for immunization series: module 18: hepatitis A, update 2019. Geneva: WHO; 2019. Available from: https://apps.who.int/iris/handle/10665/326501
  12. Schwarzinger M, Baillot S, Yazdanpanah Y, Rehm J, Mallet V. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study. J Hepatol. 2017;67(3):454-61.  https://doi.org/10.1016/j.jhep.2017.03.031  PMID: 28396173 
  13. World Health Organization (WHO). International Conference of the International Classification of Diseases and related health problems. 10th revision. ed. Geneva: WHO; 1992. 3 volumes
  14. Agence Technique de l’Information sur l’Hospitalisation. Aide à l’utilisation des informations de chaînage. [How to use de-identified patient information]. Lyon, France; 2017. Updated Oct 2017. Available from: https://www.atih.sante.fr/aide-lutilisation-des-informations-de-chainage.
  15. Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9(1):33.  https://doi.org/10.1186/1471-2458-9-33  PMID: 19161613 
  16. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223-33.  https://doi.org/10.1016/S0140-6736(09)60746-7  PMID: 19560604 
  17. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-82.  https://doi.org/10.1093/aje/kwq433  PMID: 21330339 
  18. Vaux S, Blondel C, Platon J, Fonteneau L, Pini A, Hassan E, et al. Vaccine coverage against COVID-19 and impact on the dynamics of the epidemic. Bull Epidemiol Hebd COVID-19 (Paris). 2021;12:2-13.
  19. European commission. Eurostat. Revision of the European Standard Population – Report of Eurostat's task force. 2013 edition. Luxembourg: Publications Office of the European Union; 2013.
  20. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15(3):199-236.  https://doi.org/10.1093/pan/mpl013 
  21. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; [year]. Available from: https://www.R-project.org/
  22. Van Cauteren D, Le Strat Y, Sommen C, Bruyand M, Tourdjman M, Da Silva NJ, et al. Estimated Annual Numbers of Foodborne Pathogen-Associated Illnesses, Hospitalizations, and Deaths, France, 2008-2013. Emerg Infect Dis. 2017;23(9):1486-92.  https://doi.org/10.3201/eid2309.170081  PMID: 28820137 
  23. Collier MG, Tong X, Xu F. Hepatitis A hospitalizations in the United States, 2002-2011. Hepatology. 2015;61(2):481-5.  https://doi.org/10.1002/hep.27537  PMID: 25266085 
  24. Chen CM, Chen SC, Yang HY, Yang ST, Wang CM. Hospitalization and mortality due to hepatitis A in Taiwan: a 15-year nationwide cohort study. J Viral Hepat. 2016;23(11):940-5.  https://doi.org/10.1111/jvh.12564  PMID: 27386835 
  25. Severi E, Georgalis L, Pijnacker R, Veneti L, Turiac IA, Chiesa F, et al. Severity of the clinical presentation of hepatitis A in five European countries from 1995 to 2014. Int J Infect Dis. 2022;118:34-43.  https://doi.org/10.1016/j.ijid.2022.01.053  PMID: 35134558 
  26. Wasuwanich P, So JM, Rajborirug S, Karnsakul W. Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: A nationwide population study, 1998-2020. J Viral Hepat. 2024;31(2):88-95.  https://doi.org/10.1111/jvh.13902  PMID: 38062864 
  27. Domínguez A, Torner N, Soldevila N, Varela C, Guerrero-Vadillo M, Peñuelas M, et al. Hepatitis A in Spain: Evolution of hospitalization in the period 2000-2021. PLoS One. 2025;20(9):e0332317.  https://doi.org/10.1371/journal.pone.0332317  PMID: 40991636 
  28. Ly KN, Klevens RM. Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults. J Infect Dis. 2015;212(2):176-82.  https://doi.org/10.1093/infdis/jiu834  PMID: 25637352 
  29. Horn EK, Herrera-Restrepo O, Acosta AM, Simon A, Jackson B, Lucas E. The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies. J Infect Dis. 2024;230(1):e199-218.  https://doi.org/10.1093/infdis/jiae087  PMID: 39052742 
  30. Mallet V, Beeker N, Bouam S, Sogni P, Pol S, Mallet V, et al. , Demosthenes research group. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020. J Hepatol. 2021;75(4):848-55.  https://doi.org/10.1016/j.jhep.2021.04.052  PMID: 33992699 
  31. Lee YL, Chen GJ, Chen NY, Liou BH, Wang NC, Lee YT, et al. , Taiwan HIV Study Group. Less Severe but Prolonged Course of Acute Hepatitis A in Human Immunodeficiency Virus (HIV)-Infected Patients Compared With HIV-Uninfected Patients During an Outbreak: A Multicenter Observational Study. Clin Infect Dis. 2018;67(10):1595-602.  https://doi.org/10.1093/cid/ciy328  PMID: 29672699 
  32. Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. J Hepatol. 2022;77(1):191-205.  https://doi.org/10.1016/j.jhep.2022.01.016  PMID: 35131406 
  33. Ramachandran S, Xia GL, Dimitrova Z, Lin Y, Montgomery M, Augustine R, et al. Changing Molecular Epidemiology of Hepatitis A Virus Infection, United States, 1996-2019. Emerg Infect Dis. 2021;27(6):1742-5.  https://doi.org/10.3201/eid2706.203036  PMID: 34013865 
  34. Midthun K, Ellerbeck E, Gershman K, Calandra G, Krah D, McCaughtry M, et al. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis. 1991;163(4):735-9.  https://doi.org/10.1093/infdis/163.4.735  PMID: 1849160 
  35. Pintó RM, Pérez-Rodríguez FJ, Costafreda MI, Chavarria-Miró G, Guix S, Ribes E, et al. Pathogenicity and virulence of hepatitis A virus. Virulence. 2021;12(1):1174-85.  https://doi.org/10.1080/21505594.2021.1910442  PMID: 33843464 
  36. Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak. 2016;16(1):138.  https://doi.org/10.1186/s12911-016-0377-1  PMID: 27809908 
  37. Bauer D, Farthofer A, Chromy D, Simbrunner B, Steininger L, Schmidbauer C, et al. Recent outbreaks of severe hepatitis A virus infections in Vienna. Eur J Clin Microbiol Infect Dis. 2021;40(2):335-44.  https://doi.org/10.1007/s10096-020-04028-x  PMID: 32940811 
  38. World Health Organization (WHO). WHO position paper on hepatitis A vaccines – October 2022. Wkly Epidemiol Rec. 2022;40(97):493-512.
  39. Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Byström E, et al. , ECDC HAV Expert Panel. Seroprevalence and susceptibility to hepatitis A in the European Union and European Economic Area: a systematic review. Lancet Infect Dis. 2017;17(10):e306-19.  https://doi.org/10.1016/S1473-3099(17)30392-4  PMID: 28645862 
  40. Charre C, Ramière C, Roque-Afonso AM, Chidiac C, Zoulim F, Godinot M, et al. , HAV Lyon Study Group. Hepatitis A outbreak in HIV-infected MSM and in PrEP-using MSM despite a high level of immunity, Lyon, France, January to June 2017. Euro Surveill. 2017;22(48):17-00742.  https://doi.org/10.2807/1560-7917.ES.2017.22.48.17-00742  PMID: 29208161 
  41. Săndulescu O, Mantovani S, Roque-Afonso AM, Sahin GÖ, Rajan AK, Altındiş M, et al. , ESGVH. Achieving global immunity against hepatitis A through universal vaccination: a position paper from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis. Clin Microbiol Infect. 2026;32(3):416-26.  https://doi.org/10.1016/j.cmi.2025.11.026  PMID: 41319806 
Trends and risk factors associated with hepatitis A severity and mortality in French hospitals: a national population-based study, 2013 to 2024
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Anne-Marie+Roque-Afonso&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Roque-Afonso Anne-Marie</a>, <a href="/search?value1=Charlotte+Mouliade&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mouliade Charlotte</a>, <a href="/search?value1=Lucia+Parlati&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Parlati Lucia</a>, <a href="/search?value1=Nathalie+Goutt%C3%A9&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Goutté Nathalie</a>, <a href="/search?value1=Julie+Figoni&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Figoni Julie</a>, <a href="/search?value1=Samir+Bouam&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bouam Samir</a>, <a href="/search?value1=Philippe+Sogni&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sogni Philippe</a>, <a href="/search?value1=Vincent+Mallet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mallet Vincent</a>, <a href="/search?value1=on+behalf+of+the+Demosthenes+research+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Demosthenes research group</a></span>. Trends and risk factors associated with hepatitis A severity and mortality in French hospitals: a national population-based study, 2013 to 2024. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(39):pii=2500858. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.39.2500858" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.39.2500858</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 07 Nov 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 Mar 2026 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.39.2500858
/content/10.2807/1560-7917.ES.2026.31.39.2500858
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error